1640 Efficacy and Safety of Melatonin in Neonates

Aversa, Salvatore; Marseglia, Lucia; Arco, Alba; Cusumano, Erika; Barberi, Ignazio; Reiter, R. J.; Gitto, Eloisa

doi:10.1136/archdischild-2012-302724.1640

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…155,156 Safety has not been identified as an issue in human investigations of exogenous melatonin administration, including those with high single doses, 157 high cumulative doses over several weeks 158 or months, 159 or during the study of infants and children, 76,160 including premature infants and neonates. 161 One author has called for full disclosure of animal data to families prior to prescribing melatonin, 156 as nonhuman studies have indicated a significant effect of melatonin on reproductive physiology. However, large studies with long (up to 5 years) follow-up have found no adverse effects, and particularly no alterations in puberty.…”

Section: Safetymentioning

confidence: 99%

Melatonin in Critically Ill Children

Foster

2016

J Pediatr Intensive Care

View full text Add to dashboard Cite

Melatonin, while best known for its chronobiologic functions, has multiple effects that may be relevant in critical illness. It has been used for circadian rhythm maintenance, analgesia, and sedation, and has antihypertensive, anti-inflammatory, antioxidant, antiapoptotic, and antiexcitatory effects. This review examines melatonin physiology in health, the current state of knowledge regarding endogenous melatonin production in pediatric critical illness, and the potential uses of exogenous melatonin in this population, including relevant information from basic sciences and other fields of medicine. Pineal melatonin production and secretion appears to be altered in critical illness, though understanding in pediatric critical illness is in early stages, with only 102 children reported in the current literature. Exogenous melatonin may be used for circadian rhythm disturbances and, within the critically ill population, holds promise for diseases involving oxidant stress. There are no studies of exogenous melatonin administration to critically ill children beyond the neonatal period.

show abstract

Section: Safetymentioning

confidence: 99%

Melatonin in Critically Ill Children

Foster

2016

J Pediatr Intensive Care

View full text Add to dashboard Cite

show abstract

“…It has a variety of physiological functions, not only as chronobiotic, but also visual, reproductive, cerebrovascular, and neuroendocrine functions. It is also cytoprotective and enhances free radical scavenging [4,6].…”

Section: Introductionmentioning

confidence: 99%

Melatonin as an adjuvant therapy in preterm infants with neonatal sepsis, randomized trial

El-Kabbany

El-Farghali

Khafagy

et al. 2020

Egypt Pediatric Association Gaz

View full text Add to dashboard Cite

Background: Neonatal sepsis (NS) is a systemic uncontrolled inflammatory response to an infectious agent, resulting in oxidative stress. Melatonin antioxidant and free radical scavenger proved to be safe in neonates. We aimed to evaluate the efficacy and safety of melatonin as adjuvant therapy in NS. This was an interventional trial conducted on 40 preterm neonates with NS diagnosed on the basis of clinical and laboratory criteria. They were simply randomized to melatonin treated (MT) (n = 20) and conventionally treated (CT) (n = 20) groups. Melatonin was administered at a total dose of 20 mg enterally in two divided doses of 10 mg each, 1 h apart. Malondialdehyde (MDA) was assessed in patients at enrollment, 4 and 72 h later in MT, and 72hours later in CT. Fifteen healthy matched neonates were included as a control. Results: There were no significant differences between MT and CT groups regarding baseline sepsis workup. However, total leucocytic count, absolute neutrophil count, and C-reactive protein were significantly higher and platelets were significantly lower in CT compared to MT after 72 h. MDA was doubled in CT while reduced in MT 72 h after intervention (p = 0.000). Mortality was significantly lower in MT. No side effects following melatonin administration were reported. Conclusion:Melatonin is effective and safe adjuvant for treatment of NS that improves clinical and laboratory outcomes.

show abstract